BiotechTubeBiotechTube
Home/Ensysce Biosciences/D. Lynn Kirkpatrick
DL

D. Lynn Kirkpatrick

Chief Executive Officer

Ensysce Biosciences

Therapeutic Areas

Pain ManagementOpioid Use Disorder

Ensysce Biosciences Pipeline

DrugIndicationPhase
PF614 (TAAP™ Oxycodone)Management of severe chronic painPhase 2
PF614-MPAR (Combined TAAP™/MPAR® Oxycodone)Management of severe chronic pain with overdose protectionPhase 2

Leadership Team at Ensysce Biosciences

DH
Dave Humphrey
Chief Financial Officer
WS
William Schmidt
Chief Medical Officer
JM
Jeffrey Millard
Chief Operating Officer
GB
Geoff Birkett
Chief Commercial Officer
LP
Linda Pestano
Chief Development Officer
View full Ensysce Biosciences profile